Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 13:23:517-546.
doi: 10.1146/annurev-bioeng-112619-044026. Epub 2021 May 11.

Cell and Tissue Therapy for the Treatment of Chronic Liver Disease

Yaron Bram  1 , Duc-Huy T Nguyen  1 , Vikas Gupta  1 , Jiwoon Park  2 , Chanel Richardson  3 , Vasuretha Chandar  1 , Robert E Schwartz  1   2
Affiliations
Review

Cell and Tissue Therapy for the Treatment of Chronic Liver Disease

Yaron Bram et al. Annu Rev Biomed Eng. .

Abstract

Liver disease is an important clinical problem, impacting 600 million people worldwide. It is the 11th-leading cause of death in the world. Despite constant improvement in treatment and diagnostics, the aging population and accumulated risk factors led to increased morbidity due to nonalcoholic fatty liver disease and steatohepatitis. Liver transplantation, first established in the 1960s, is the second-most-common solid organ transplantation and is the gold standard for the treatment of liver failure. However, less than 10% of the global need for liver transplantation is met at the current rates of transplantation due to the paucity of available organs. Cell- and tissue-based therapies present an alternative to organ transplantation. This review surveys the approaches and tools that have been developed, discusses the distinctive challenges that exist for cell- and tissue-based therapies, and examines the future directions of regenerative therapies for the treatment of liver disease.

Keywords: cell therapy; liver; stem cell biology; tissue engineering.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Architecture of the liver from the macro to the micro scale. (a) An example of the gross structure of the liver is shown. (b) When zoomed in, the lobular architecture of the liver, including the vascular and biliary components, is revealed. (c) Further examination reveals the cellular composition and architecture of the lobule.
Figure 2
Figure 2
Different sources of hepatocytes for therapeutic and scientific applications. Many different cell types and sources can be differentiated, transdifferentiated, reprogrammed, or expanded to generate hepatocytes for clinical and scientific applications.
Figure 3
Figure 3
Liver tissue engineering approaches. Hepatic tissue engineering consists of cellular components and engineered 3D scaffolds that are assembled and transplanted in vivo to yield hepatic function.
See this image and copyright information in PMC

References

    1. Marcellin P, Kutala BK. 2018. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 38:2–6 - PubMed
    1. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, et al. 2020. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol 5(3):245–66 - PMC - PubMed
    1. Desai AP, Mohan P, Roubal AM, Bettencourt R, Loomba R. 2018. Geographic variability in liver disease-related mortality rates in the United States. Am. J. Med 131:728–34 - PMC - PubMed
    1. Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younos Z. 2020. The growing burden of disability related to chronic liver disease in the United States: data from the Global Burden of Disease Study 2007–2017. Hepatol. Commun 5:749–59 - PMC - PubMed
    1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. 2019. Burden of liver diseases in the world. J. Hepatol 70:151–71 - PubMed

Publication types